Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Zomedica Corp. reported revenue of $32M, up 17.4% year over year. Operating margin was -263.4% and net margin -255.6%, on a free-cash-flow margin of -56.9% with capital expenditure at 1.8% of revenue. Every figure is computed directly from ZOMDF's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $32M | -263.4% | -255.6% |
| FY2024 | $27M | -187.1% | -172.2% |
| FY2023 | $25M | -171.8% | -137.1% |
| FY2022 | $19M | -115.8% | -89.9% |
| FY2021 | $4M | -517.1% | -444.8% |
How does ZOMDF compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.